Abstract

Drug-drug interactions occur when the effects of one medication are altered by the concomitant use of another drug. Understanding the potential interactions between drugs is crucial for optimizing treatment outcomes and minimizing adverse effects. This study aimed to investigate the drug-drug interaction between Pravastatin, a commonly used cholesterol-lowering medication, and Gliclazide, an oral hypoglycemic agent, in animal models. Male Wistar rats were divided into four groups: Group 1 received Pravastatin alone, Group 2 received Gliclazide alone, Group 3 received both drugs concurrently, and Group 4 served as a control. Various pharmacokinetic and pharmacodynamic parameters were assessed, including plasma drug concentrations, lipid profiles, blood glucose levels, and liver function tests. The results revealed a significant increase in the plasma concentration of Pravastatin in the presence of Gliclazide, suggesting a potential pharmacokinetic interaction. Furthermore, the combined administration of Pravastatin and Gliclazide led to improved lipid profiles and better glycemic control compared to individual drug treatments. However, liver function tests indicated a mild elevation in liver enzymes with the combination therapy, warranting further investigation. Overall, this study demonstrates a possible drug-drug interaction between Pravastatin and Gliclazide, emphasizing the need for cautious co-administration and close monitoring in clinical practice.